Tag: Pharmaceuticals

India Large Volume Parenterals Market Worth $121.7 Million By 2025

The India large volume parenterals (LVP) market size is expected to reach USD 121.7 million by 2025 at a 7.1% CAGR during the forecast period, according to a new report by Grand View Research, Inc. LVPs offer a faster method for the administration of drugs to patients during surgery or while recovering in the hospital. Rising preference by physicians for single-dose administration of drugs is responsible for the growing demand for LVP. 

C0WDHC Studio shot of One Touch Ultra diabetes glucose meter and vial of test strips.

Parenterally administered drugs gain quick access to systemic circulation with complete drug absorption. These drugs have high bioavailability and reach the site of action faster than drugs administered orally, thus delivering an immediate physiological response in clinical conditions such as shock, asthma, and cardiac arrest. Moreover, parenteral administration is essential for drugs that do not provide therapeutic effect orally or that are broken down by digestive secretions such as hormones (e.g. insulin) and antibiotics.

There is a rise in healthcare expenditure in India where households incur a high monthly per-capita out-of-pocket expense on account of diseases such as cancer, followed by injuries and cardiovascular disorders. In such disease conditions, the patient has to incur the cost of LVP as well as make a repeat purchase over the period of treatment.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/india-large-volume-parenteral-lvp-market

Further key findings from the study suggest:

  • The Indian pharmaceutical industry is growing at a rapid pace and remains one of the largest contributors to the country’s economy. India’s pharma sector is placed third in terms of volume and 14th in terms of value in global rankings
  • By application, the India LVP market is categorized into therapeutic injections, fluid balance injections, and nutritious injections. Of these, nutritious injections dominated the market in terms of revenue in 2017
  • Based on volume, the LVP market is grouped into 100 ml, 250 ml, 500 ml, 1000 ml, and 2000 ml. Of these, the 100 ml injectable segment is expected to exhibit the fastest growth rate in the coming years
  • Based on end use, the market is divided into hospitals & other healthcare facilities and home care. Hospitals & other healthcare facilities held a majority share in 2017
  • Market players and manufacturers have developed a supply chain contract with reputed hospitals, leading to a better hold over the market. Some of these players are Fresenius Kabi AG; Baxter; Otsuka Pharmaceutical Co., Ltd.; and BML Parenteral Drugs.

Pregnancy Care Products Market Size Worth $33.22 Million By 2025

The global pregnancy care products market size is expected to reach USD 33.22 million by 2025 at a 5.1% CAGR during the forecast period, according to a new report by Grand View Research, Inc. Increasing awareness regarding use of personal care products during pregnancy and high adoption of organic products are driving the market.

A shift in trend toward adoption of organic maternity personal care products owing to safety concerns over chemical-based products is changing the scenario of the overall market. Furthermore, new as well as existing players are introducing organic or herbal variants to increase their market presence and product positioning. In addition, rising awareness and increasing influence of advertising and social media campaigns are boosting the adoption of pregnancy care products.

Doctors do not recommend the use of certain chemicals such as salicylic acid, retinol, toluene, and beta hydroxy acids during pregnancy as they pose a threat to both mother and baby. This has impeded the growth of chemical-based pregnancy care products.

Stretchmark minimizers is the largest segment of the global pregnancy care products market owing to rising concern of stretchmarks during gestation period. Breast creams and toning/firming lotions are expected to experience lucrative demand over the forecast period owing to increasing awareness and rising focus regrading post pregnancy body. Asia Pacific emerged as the dominant regional market owing to highest number of pregnancies and rising cognizance regarding adoption of pregnancy care products.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/pregnancy-care-products-market

Further key findings from the report suggest:

  • Stretchmark minimizers emerged as the largest segment owing to their high demand during pregnancy and rising awareness regarding the product
  • Asia Pacific dominated the market in 2017. Higher number of births and rising awareness among expecting mothers have facilitated the dominance of this region
  • Latin America is projected to witness rapid growth during the forecast period owing to rapid adoption of organic variants of pregnancy care products and increased product availability owing to telemarketing and other social media platforms
  • Some of the key players are Mama Mio US Inc.; Noodle & Boo Novena Maternity; Expanscience Laboratories, Inc.; E.T. Browne Drug Co., Inc.; and Clarins Group.

Sickle Cell Disease Treatment Market Worth $5.5 Billion by 2023

The global sickle cell disease treatment market size is expected to reach USD 5.5 billion by 2023, according to a new report by Grand View Research, Inc., exhibiting a 14.3% CAGR during the forecast period. Several factors such as increase in investments for R&D, growing target population, and favorable government initiatives are anticipated to drive the market.

Currently available treatments for sickle cell disease (SCD) usually provide symptomatic relief and palliative care. These treatment methods generally include blood transfusions, bone marrow transplant, and pharmacotherapy. Although bone marrow transplant is the only potentially curative treatment, it is recommended only to a small percentage of patients. The market has only two approved products—hydroxyurea and Endari.

High unmet medical needs, strong pipeline, and growing patient pool are key factors expected to influence market growth. In recent years, demand for cost-effective drugs and gene therapies for SCD has increased owing to the unavailability of a permanent cure and risks associated with bone marrow transplant.

Expected launch of late-stage pipeline drugs such as voxelotor, crizanlizumab, Altemia, and rivipansel is projected to drive the sickle cell disease market during the forecast period. Healthcare initiatives undertaken by respective economies are crucial for curbing the financial burden of the disease as well as for increasing access to healthcare facilities and providing various services for early diagnosis, subsequent treatment, and palliative care.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/sickle-cell-disease-treatment-market

Further key findings from the report suggest:

  • Currently, 20 to 25 million people worldwide are reportedly living with sickle cell disease and about 300,000 infants are born annually with the disease
  • The U.S. dominated the global market and is projected to maintain its position through 2023, owing to rise in incidence of diseases and launch of promising pipeline candidates
  • Among treatments, blood transfusion held the largest share in 2017, followed by pharmacotherapy. However, it is anticipated that pharmacotherapy will lead the market by 2023, supported by a strong pipeline and several promising drug launches
  • Emmaus Medical, Global Blood Therapeutics, bluebird bio, Pfizer, and Novartis are some of the key players operating in this market
  • Emmaus Medical is projected to dominate the SCD pharmaceutical market in 2023, supported by strong sales of Endari
  • Currently, 37 pipeline drugs are in various clinical development stages and significant sales contribution is expected from promising candidates such as voxelotor (Global Blood Therapeutics), crizanlizumab (Novartis), Altemia (Sancilio), and rivipansel (Pfizer).

Myeloproliferative Disorders Drugs Market Worth $9.26 Billion By 2023

The global myeloproliferative disorder drugs market size is expected to be valued at USD 9.26 billion by 2023, as per a new report by Grand View Research, Inc., expanding at a CAGR of 3.4% during the forecast period. Availability of novel drugs, the presence of a strong pipeline, rising incidence of myeloproliferative disorders due to changing lifestyles, growing geriatric population, and increasing public awareness are some of the primary growth stimulants for the market. Therapeutic development in the second-line setting for Jakafi-intolerant patients is estimated to work in favor of the Ph- MPNs market.

Chronic myeloproliferative disorders are rare hematological malignances that involve the abnormal accumulation of mature myeloid cells (red blood cells, granulocytes, and platelets) and their precursors (myelocytes, metamyelocytes, nucleated red blood cells, and megakaryocytes) in the peripheral blood and bone marrow. This class of disorder includes four main myeloproliferative diseases, which are further categorized by the presence of the Philadelphia chromosome.

There is a higher incidence of myeloproliferative disorders in North America and Western Europe as compared to East-Asian countries. Most patients are diagnosed with MPNs after 60 years of age, however, the diseases can occur in any age group. The U.S. will be the most prominent market for myeloproliferative disorders drugs owing to the presence of a large target population.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/myeloproliferative-disorders-drugs-market

Further key findings from the study suggest:

  • The U.S. accounted for more than 45.0% of the market in 2017. Spiraling adoption of novel therapeutics and multiple product launches during the forecast period are anticipated to support the prominence of the market in the global arena over the coming years
  • Strong unmet needs are likely to shape the future of the market and encourage the development of breakthrough first-in-class therapies. Opportunities remain in the Ph- MPNs setting where there exists an unmet need for a safer drug than Jakafi with higher cure rates and lesser allergic effects
  • Some of the key market participants are Novartis, Bristol-Myers Squibb, Pfizer, Takeda, Incyte, and Teva. Primary go-to strategies of prominent players include collaborations for the development and regional expansion in emerging markets.

Huntington’s Disease Treatment Market Size Worth $1.5 Billion by 2023

The global huntington’s disease treatment market size is expected to be valued at USD 1.5 billion by 2023, as per a new report by Grand View Research, Inc., registering a CAGR of 38.2% during the forecast period. The market is largely driven by factors such as rapid uptake of disease-modifying therapies, increased adoption of novel therapeutics, and increase in R&D activities.

huntington’s disease

Huntington’s disease is an inherited neurodegenerative disorder characterized by a combination of motor, cognitive, and psychiatric symptoms. Currently, only two symptom-alleviating therapies are specifically approved for this disorder: Xenazine and Austedo. Off-label medications are used extensively due to lack of approved alternatives.

The pipeline for Huntington’s disease is expected to witness rapid developments in the coming years as disease-modifying drugs transform the market landscape. Improved disease understanding has led to significant progress in the development of therapeutic approaches aimed at modifying specific changes linked to the causative mutation. The potential role of RNA antisense technology and stem cell therapy are under active clinical investigation. Wave Life Sciences and Ionis Pharma’s antisense oligonucleotides aim to target underlying disease cause and are expected to contribute significantly to market growth.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/huntingtons-disease-treatment-market

Further key findings from the report suggest:

  • Teva is projected to become the market leader, capturing more than 45% of the market in 2023, driven by Austedo’s rapid uptake and improved efficacy profile compared to its competitors. Teva’s Huntexil is expected to be the only new symptom-alleviating drug to be launched during the forecast period
  • Raptor’s RP103 is expected to face head-to-head competition from Prana Biotech’s Phase II drug PBT2 to be the first disease modifying therapy to be launched in the market
  • Currently, 23 products are under clinical investigation for Huntington’s disease, out of which, one is in Phase II/III each, thirteen in Phase II trials, two in Phase Ib/IIa, six in pre-clinical trials, and one in discovery phase
  • EU5 will remain the second largest market with more than 15% share in 2023, driven by rising disease prevalence, novel drug launches, and increase in R&D activities
  • Companies are now focusing on development of treatments that can be injected directly in the brain to directly inhibit the formation of mutant HTT protein, instead of targeting the mutant protein
  • Drugs with novel targets in early-phase development include Stealth Biotherapeutics’ SBT-20 (mitochondria-targeted cytoprotective peptide), Cellavita + Azidus Brazil’s Cellavita HD (stem cell therapy), Sangamo/ Shire’s mHTT ZFP (zinc finger protein), and UniQure’s AMT-130 (gene therapy).

South East Asia Nutraceutical Excipients Market Worth $1.03 Billion By 2025

The South East Asia nutraceutical excipients market size is expected to reach USD 1.03 billion by 2025 at an 8.22% CAGR, according to a new report by Grand View Research, Inc. Increasing health consciousness and consequently increasing demand for nutraceuticals among consumers in South East Asia (SEA) are expected to drive market growth.

South East Asian countries are recognized as hubs for innovation as far as new ingredients and functional foods are concerned. Major changes in the urban lifestyle, high dependence on domestic consumption, and rising disposable income of consumers are key factors boosting the nutraceutical industry in these counties.

Many international nutraceutical manufacturers seek entry into the SEA market owing to the high potential for revenue generation through consumer behavior patterns in this region. For instance, in January 2018, ChromaDex introduced its TRU NIAGEN supplement in Singapore through retail partnerships with Watsons. It is the first and only commercial form of nicotinamide riboside, which supports healthy aging by providing protection against cellular stress, boosting energy, and inducing DNA repair.

Countries like Myanmar, Indonesia, and Philippines present higher prevalence of health issues such as hypertension, obesity, and diabetes, thus exhibiting demand for nutraceutical products. Rising investments by multinational nutraceutical manufacturers in this region are also expected to drive demand for local excipient suppliers.

Furthermore, governments of countries in this region are making efforts to introduce more harmonized regulations for the pharma and nutraceutical industry. Better regulatory standards are expected to enhance penetration of nutraceutical excipient manufacturers in the coming years.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/south-east-asia-nutraceutical-excipients-market

Further key findings from the report suggest:

  • The South East Asia nutraceutical excipients market is driven by players such as Roquette, Dow Chemical Company, SGS, and Azelis
  • Film coating excipients held the largest revenue share owing to rapid adoption in tablet formulations to overcome key challenges in nutraceutical manufacturing
  • Growing demand for low-calorie sugar substitutes to overcome the undesirable taste of most nutraceuticals is attributive to the fastest growth of the sugars and polyols segment
  • Thailand is projected to witness the fastest growth owing to changing trends in the health and wellness industry. Government initiatives such as the Universal Coverage Scheme further contribute to market growth
  • International companies seek entry into the market through distribution partnerships with local players or establishment of subsidiaries in prominent markets
  • Some key players in the South East Asia nutraceutical excipients market are SPI Pharma; DuPont Nutrition and Health; The Dow Chemical Company; Barentzk; Cargill Inc.; BASF SE; JRS Pharma; BEHN MEYER; and Sensient Colors LLC.

Drug Discovery Outsourcing Market Worth $4.4 Billion By 2025

The global drug discovery outsourcing market size is expected to reach USD 4.44 billion by 2025 at an 8.14% CAGR, according to a new report by Grand View Research, Inc. Urging need to identify potential drug candidates for various chronic diseases is anticipated to fuel growth.

Technological advances in in silico drug designing and accelerating integration of Artificial Intelligence (AI) in drug discovery are driving industry progress. Multiple applications of AI algorithms in drug design and discovery provide opportunities for players to offer specialized drug discovery services. It is useful for processes such as target and compound selection, predictive analytics, screening, and drug repurposing.

Projected rise in adoption of outsourcing over the forecast period is expected to boost market revenue generation. Half of the drug discovery processes are anticipated to be outsourced, thereby creating massive opportunities for CROs, CMOs, and CDMOs to expand their market presence.

Number of collaborations among these organizations, key pharmaceutical players, and several universities has increased over the past few years. This rise in alliance further supports the projected increase in growth potential.

High cost and high risk of drug failure are major challenges faced in drug discovery. However, advances in technology that increase efficiency of drug discovery, coupled with increased adoption of highly advanced technology to provide specialized services, allow outsourcing companies to overcome these challenges.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/drug-discovery-outsourcing-market

Further Key Findings From the Report Suggest:

  • Escalating incidence of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD) is projected to indirectly propel market growth. Advancements in technologies, such as emergence of Artificial Intelligence (AI) in the pharmaceutical industry, is also anticipated to accelerate industry progress
  • Moreover, increasing incidences of antibiotic resistance as well as drug resistance have improved focus on discovery of novel compounds to treat conditions such as Multidrug-Resistant TB (MDR-TB)
  • Based on workflow, lead identification and candidate optimization is slated for impressive growth owing to high bottlenecks in this workflow segment
  • By therapeutic area, oncology drug discovery outsourcing is fueled by increasing demand for oncology solutions, coupled with expanding government support in cancer research
  • North America dominates the global market owing to high focus on R&D in identification of novel drug candidates, along with presence of key players
  • Asia Pacific is projected to witness the fastest growth over the forecast period as a result of increasing number of CRO, CMOs, and CDMOs in emerging countries. Rising trend of outsourcing manufacturing and R&D activities to countries such as China and India will aid growth in the region
  • Some of the major players are Charles River; EVOTEC, Laboratory Corporation of America Holdings; GenScript, Merck & Co., Inc.; Jubilant Biosys; Thermo Fisher Scientific, Inc.; Oncodesign; Albany Molecular Research, Inc.; WuXi AppTec; Dalton Pharma Services; Pharmaceutical Product Development, LLC; DiscoverX Corporation; and QIAGEN
  • Collaboration of players with key pharmaceutical companies and academics and research centers is observed to increase in recent years.

Opioids Market Size Worth $29.4 Billion By 2026

The global opioids market size is estimated to reach USD 29.4 billion by 2026, according to a new report by Grand View Research, Inc., expanding at a CAGR of 1.8% over the forecast period. Growing geriatric population, coupled with increasing focus on palliative care, is estimated to drive the market. Moreover, increasing geographical expansions by market players is expected to fuel growth.

Rising prevalence of disease conditions with chronic pain, such as cancer, lower back pain, arthritis, and fibromyalgia, is driving the opioids market. Substantial rise in road accidents and trauma, coupled with constantly increasing cases of surgical procedures, is also driving demand for opioid-based pain management solutions.

On the basis of product, ER was the dominant segment in 2018 owing to its high usage in chronic pain management. However, the abuse and misuse of these drugs have resulted in a serious public health crisis.

North America led the market in 2018 with a share of 55.5% in terms of revenue. One of the major reasons for its dominance is rising geriatric population with terminal conditions, such as rheumatoid arthritis. However, opioid abuse in U.S. has been rising at an alarming rate. Overdose has killed over 28,000 people in 2014 alone. Almost half of those deaths were caused by prescription drugs. Hence, drug abuse has been declared a “public health emergency” in U.S. and this is likely to limit market growth in North America.

According to the federal government, around 4,000 Canadians died due to opioid-related overdose in 2017, which is a 34% jump from the previous year. Globally, Canadians are one of the highest users of prescription opioids and this rate, along with associated deaths and hospital visits, has been growing rapidly. To combat this, Health Canada aims to restrict the marketing of such drugs.

The federal government is calling on pharmaceutical companies to stop marketing opioids. For instance, Purdue Pharma has stopped marketing its opioids in Canada, thereby limiting the growth of the North America market. The company has, in fact, shifted its focus to other regions, such as Asia Pacific, to retain its hold in the market. APAC is likely to witness the fastest growth in the coming years.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/opioids-market

Further key findings from the study suggest:

  • Extended release was the largest product segment in 2018 due to its high usage in chronic pain management
  • Cancer pain was the largest pain relief segment in 2018 owing to global increase in prevalence of cancer
  • North America was the largest regional market in 2018, driven by presence of key players and highest use of prescription opioids
  • Europe was the second-largest regional market in 2018, primarily fueled by growing geriatric population
  • Asia Pacific is expected to witness the fastest growth over the forecast period due to increase in geriatric population, coupled with shifting focus of key players towards this region in order to strengthen their position
  • Some of the key players are Purdue Pharma L.P; West-Ward Pharmaceuticals Corporation; Allergan; Pfizer, Inc.; Janssen Pharmaceuticals, Inc.; Egalet Corporation; and Sun Pharmaceutical Industries Limited. Most key players are focusing on entering untapped regions and expanding their product portfolios.

Thalassemia Market Size Worth $3.53 Billion By 2022

The global thalassemia market size is expected to be valued at USD 3.53 billion by 2022, as per a new report by Grand View Research, Inc., exhibiting a CAGR of 10.8% during the forecast period. Increase in demand for a universal cure, rise in awareness about the disease, and technological advancements are likely to increase the adoption of gene therapies. 

Thalassemia is a general term for a group of inheritable blood disorders, in which the body produces abnormal hemoglobin, resulting in the destruction of red blood cells. This ultimately leads to anemia. There are two main types of thalassemia: alpha-thalassemia and beta-thalassemia, the latter being more serious. Beta-thalassemia is a common autosomal recessive disorder worldwide and it is relatively rare in the U.S.

Increase in the incidence of thalassemia is anticipated to fuel market growth. Despite technological advancements, the unmet need for a reliable treatment option still exists. Treatment of thalassemia is mostly restricted to regular blood transfusions and iron chelation therapy. Drugs prescribed for thalassemia mostly cure symptoms and side effects such as anemia, iron overload, and vitamin deficiency. However, gene therapy is emerging as a reliable treatment option for the disease.

Prevalence of thalassemia is reported to increase gradually over the years across different regions. This can be attributed to population migration, intermarriages, and genetic and environmental factors prompting the condition and its implications.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/thalassemia-market

Further Key Findings From the Report Suggest:

  • The global thalassemia market is expected to expand at a lucrative CAGR of 10.8% over the forecast period because of improved safety and efficacy profiles of gene therapy
  • India and Thailand are expected to offer lucrative growth opportunities for market expansion
  • Some of the key players in the industry with promising pipeline products are bluebird bio, Inc.; Acceleron Pharma; Novartis AG; Incyte Corporation; Kiadis Pharma; Gamida Cell; and Celgene Corporation
  • Blood transfusion and iron chelation therapies were the preferred treatment options for thalassemia in 2016, owing to their higher usage, ease, and affordability. However, the segments are likely to lose market share over the forecast period due to the increase in adoption of curative gene therapy
  • Regionally, among the seven major markets, EU5 held the dominant share in terms of revenue in 2016, followed by U.S. and Japan
  • U.S. is expected to be the fastest-growing region with a lucrative CAGR from 2016 to 2022 due to an increase in the prevalence of the disease and presence of well-established healthcare services

Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Worth $3.4 Billion By 2025

The global acute lymphocytic/lymphoblastic leukemia therapeutics market is expected to reach USD 3.4 billion by 2025, according to a new report by Grand View Research, Inc. Increasing public and private initiatives for diagnosis of Acute Lymphoblastic Leukemia (ALL), rising number of bone marrow biopsies, and availability of other treatment options are factors expected to increase the adoption of ALL procedures. For instance, The Baby Friendly Initiative Program by UNICEF (UK) and SickKids-Caribbean Initiative, a collaborative approach between hospitals and healthcare institutions in Canada, aim to provide free diagnosis and treatment services to infants suffering from ALL, who meet certain eligibility criteria.

Furthermore, rising incidence of ALL is anticipated to boost the market. The disease is prevalent among children below 5 years of age. The risk of contracting ALL is the highest between the ages of 0 and 20. On the other hand, adults are also at a risk of developing this condition. The median age of men diagnosed with this condition is approximately 55 years.

Click the link below:
http://www.grandviewresearch.com/industry-analysis/acute-lymphocytic-lymphoblastic-leukemia-therapeutics-market

Further Key Findings From the Report Suggest:

  • Chemotherapy dominated the market in 2016 owing to its high prescription rate, presence of a wide product portfolio, and easy availability of products
  • Targeted therapy is anticipated to be the most preferred therapy in comparison to other types of therapies due to its associated benefits such as target-specific action and its ability to prevent collateral damage, leading to faster recovery
  • Precursor B-ALL dominated the market in 2016 and is expected to be the fastest growing segment during the forecast period due to increasing prevalence of BCR-ABL and Burkitt leukemia, which are its subtypes
  • North America dominated the market in 2016 owing to factors such as the increase in demand for chemotherapy regimen such as CALGB 8811 and oncaspar in this region
  • Asia Pacific is anticipated to be the fastest growing region with a lucrative CAGR during the forecast period due to growing awareness about ALL. Furthermore, the rising disposable income and presence of large population base are some of the factors expected to propel the growth in this region
  • Key players in this industry are Erytech Pharma, Spectrum Pharmaceuticals, Inc., Pfizer, Inc., Sigma-Tau s.p.a., and Genzyme Corporation
  • Key players are focusing on strategies such as expansion of product portfolio and collaborations. For instance, in June 2017, Bristol-Myers Squibb Company and QIAGEN entered into an agreement to use Next-Generation Sequencing (NGS) technology to develop gene expression profiles for immune-oncology therapies